© 2024 KGOU
Colorful collared lizard a.k.a mountain boomer basking on a sandstone boulder
News and Music for Oklahoma
Play Live Radio
Next Up:
0:00 0:00
Available On Air Stations

U.S. Drug Giant Pfizer To Buy Ireland-Based Allergan


This is one of the biggest health care mergers in history. Pfizer, the giant American drug maker, says today it has clinched its deal to buy Ireland's Allergan, a deal that is said to be worth $160 billion. This deal is controversial because Pfizer also says it plans to move its headquarters to Dublin, Ireland and avoid paying U.S. tax rates. NPR's John Ydstie has been covering this deal. John, good morning.


INSKEEP: OK, so I gave a number there. But how big is big in this case?

YDSTIE: Well, Pfizer is one of the biggest drug companies in the U.S. and one of the oldest as well. It made painkillers during the Civil War and made penicillin during the Second World War. Right now, it makes blockbuster drugs, like Viagra and Lipitor. And in purchasing Allergan, it will also add Botox to its stable of drugs. Allergan itself is the product of a number of mergers. And though it’s based in Ireland, most of its operations are in New Jersey. The deal is one of a wave of mergers in the health care industry this year. The merger mania is partly driven by companies rearranging to be more competitive in the Obamacare era. Another reason is that interest rates are so low. And companies can borrow very cheaply to do these deals.

INSKEEP: Well, what does this mean for Pfizer's tax rates?

YDSTIE: Well, it means Pfizer's tax rates would go down. If you look at 2014, Pfizer paid a rate of about 25 percent in U.S. taxes. And Allergan paid a rate of about 5 percent in Ireland. So you can see the company's motivation. Now, Pfizer tries to play this down, but the company's CEO, Ian Read, has said the high U.S. tax rate is making his company uncompetitive globally. He's also said the company's being forced to compete with one arm tied behind its back.

INSKEEP: Could the United States shoot down this merger for that reason?

YDSTIE: Well, you know, at this point, analysts say it's not likely. The administration has tried to write rules to curb the practice. And it announced a second set of rules late last week. These kinds of mergers, called inversions, are costing the U.S. Treasury billions of dollars a year in lost tax revenue. And President Obama has said they are unpatriotic. There's also a lot of criticism from lawmakers on Capitol Hill. But the Treasury Department is very limited in what it can do. The administration has been calling on Congress to do something. But given the dysfunction in Washington, I think that seems unlikely to happen any time soon.

INSKEEP: NPR's John Ydstie, thanks very much.

YDSTIE: You're welcome, Steve. Transcript provided by NPR, Copyright NPR.

John Ydstie has covered the economy, Wall Street, and the Federal Reserve at NPR for nearly three decades. Over the years, NPR has also employed Ydstie's reporting skills to cover major stories like the aftermath of Sept. 11, Hurricane Katrina, the Jack Abramoff lobbying scandal, and the implementation of the Affordable Care Act. He was a lead reporter in NPR's coverage of the global financial crisis and the Great Recession, as well as the network's coverage of President Trump's economic policies. Ydstie has also been a guest host on the NPR news programs Morning Edition, All Things Considered, and Weekend Edition. Ydstie stepped back from full-time reporting in late 2018, but plans to continue to contribute to NPR through part-time assignments and work on special projects.
Steve Inskeep is a host of NPR's Morning Edition, as well as NPR's morning news podcast Up First.
More News
Support nonprofit, public service journalism you trust. Give now.